Mary Imig, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Imig’s office at (408) 356-0431 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G61752 · Current
Licensed to practise in California · since 1987 · expires 2027-07-31 · Howard University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Los Gatos Surgical CenterAmbulatory Surgery Center · Los Gatos, CA0.63% owner since 2005 · accredited by AAAHCAccreditation Renewed6 inspections, 3 with deficiencies · last 2025-04-03
- Los Gatos Surgical CenterSan Jose, CA0.63% owner since 2005 · accredited by AAAHCClosed1 inspection · last 2021-08-10
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$46,606
Medicare paid this office $46,606 for 373 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 233 | $11,147 | $48 |
| Short return visit (20+ min) | 96 | $8,201 | $75 |
| Return visit (30+ min) | 61 | $7,210 | $109 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 107 | $6,129 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 22 | $2,657 | $116 |
See all 11 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 233 | $11,147 | $48 |
| Short return visit (20+ min) | 96 | $8,201 | $75 |
| Return visit (30+ min) | 61 | $7,210 | $109 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 107 | $6,129 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 22 | $2,657 | $116 |
| New patient visit (45+ min) | 11 | $1,676 | $152 |
| New patient visit (30+ min) | 16 | $1,605 | $100 |
| Complete ultrasound scan of pelvis | 11 | $1,001 | $91 |
| Short return visit | 14 | $727 | $52 |
| New patient visit (15+ min) | 11 | $587 | $53 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 14 | $224 | $14 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
| Removal or shaving of skin growth | 1-10 | None |
Who their Medicare patients are
373 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.74. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 52% · Cancer 16% · Diabetes 14% · Coronary heart disease 13% · Atrial fibrillation 12% · Depression 10% · Chronic kidney disease 7% · Heart failure 6% · COPD 6% · Stroke 4%.
The office billed $176,827, Medicare allowed $58,653 and paid $46,606; for 664 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 373 | 664 | 73 | 0.74 | $176,827 | $46,606 |
| 2023 | 332 | 605 | 72 | 0.73 | $170,921 | $46,801 |
| 2022 | 326 | 681 | 72 | 0.70 | $142,791 | $46,898 |
| 2021 | 322 | 627 | 72 | 0.71 | $179,179 | $44,260 |
| 2020 | 293 | 576 | 72 | 0.68 | $181,257 | $40,514 |
| 2019 | 310 | 723 | 72 | 0.68 | $205,494 | $42,822 |
| 2018 | 166 | 280 | 72 | 0.67 | $76,832 | $17,004 |
| 2017 | 249 | 436 | 72 | 0.73 | $116,338 | $27,717 |
| 2016 | 289 | 547 | 72 | 0.75 | $155,734 | $35,488 |
| 2015 | 220 | 496 | 72 | 0.68 | $100,318 | $30,809 |
| 2014 | 284 | 750 | 71 | 0.65 | $86,023 | $43,690 |
| 2013 | 147 | 489 | 71 | 0.69 | $42,238 | $21,445 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 191 | $9,128 | $48 |
| Return visit (30+ min) | 63 | $8,751 | $120 |
| Short return visit (20+ min) | 92 | $7,293 | $75 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 85 | $4,750 | $56 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,266 | $113 |
| Complete ultrasound scan of pelvis | 15 | $1,692 | $106 |
| New patient visit (30+ min) | 13 | $1,225 | $94 |
| Influenza vaccine split virus, preservative free | 14 | $1,007 | $72 |
| Biopsy of lining of uterus | 13 | $962 | $74 |
| Short return visit | 15 | $777 | $49 |
| Administration of influenza virus vaccine | 15 | $554 | $37 |
2022: 8 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 215 | $10,260 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 155 | $8,533 | $55 |
| Short return visit (20+ min) | 86 | $8,184 | $76 |
| Return visit (30+ min) | 52 | $6,753 | $114 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 27 | $3,732 | $120 |
| New patient visit (30+ min) | 16 | $1,602 | $100 |
| Complete ultrasound scan of pelvis | 13 | $1,479 | $106 |
| Short return visit | 17 | $828 | $49 |
2021: 8 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 202 | $9,940 | $49 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 174 | $9,847 | $57 |
| Return visit (30+ min) | 56 | $7,435 | $109 |
| Short return visit (20+ min) | 71 | $6,293 | $77 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,628 | $136 |
| New patient visit (30+ min) | 15 | $1,474 | $98 |
| New patient visit (45+ min) | 11 | $1,470 | $134 |
| Short return visit | 11 | $474 | $43 |
2020: 6 services
| Return visit (30+ min) | 106 | $11,864 | $93 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 192 | $9,437 | $49 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 121 | $6,746 | $56 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 16 | $2,318 | $129 |
| Short return visit (20+ min) | 33 | $2,275 | $63 |
| Administration of influenza virus vaccine | 12 | $251 | $21 |
2019: 6 services
| Return visit (30+ min) | 91 | $12,226 | $102 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 187 | $8,875 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 117 | $6,426 | $55 |
| Short return visit (20+ min) | 46 | $3,173 | $63 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 16 | $2,630 | $120 |
| New patient visit (45+ min) | 13 | $1,559 | $120 |
2018: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 107 | $4,877 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 55 | $3,041 | $55 |
| Short return visit (20+ min) | 43 | $2,849 | $62 |
| Return visit (30+ min) | 24 | $2,651 | $91 |
2017: 6 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 140 | $6,430 | $46 |
| Short return visit (20+ min) | 80 | $6,318 | $63 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 97 | $5,390 | $56 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 16 | $2,190 | $115 |
| Return visit (30+ min) | 13 | $1,317 | $101 |
| Short return visit | 13 | $505 | $39 |
2016: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 205 | $9,291 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 120 | $6,643 | $55 |
| Short return visit (20+ min) | 69 | $5,384 | $59 |
| New patient visit (30+ min) | 19 | $1,767 | $93 |
| Short return visit | 16 | $624 | $39 |
2015: 7 services
| Short return visit (20+ min) | 83 | $5,790 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 119 | $5,401 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 92 | $5,053 | $55 |
| Return visit (30+ min) | 22 | $2,712 | $90 |
| Dxa bone density measurement of hip, pelvis, spine | 34 | $1,730 | $51 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $1,566 | $112 |
| Short return visit | 17 | $672 | $40 |
2014: 7 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 218 | $9,552 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 144 | $7,707 | $54 |
| Short return visit (20+ min) | 109 | $7,703 | $59 |
| Return visit (30+ min) | 51 | $5,295 | $84 |
| Dxa bone density measurement of hip, pelvis, spine | 54 | $3,312 | $61 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 22 | $468 | $21 |
| Manual urinalysis test with examination using microscope, non-automated | 12 | $68 | $4 |
2013: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 85 | $3,769 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 62 | $3,313 | $53 |
| Return visit (30+ min) | 30 | $3,109 | $89 |
| Short return visit (20+ min) | 36 | $2,343 | $56 |
| Dxa bone density measurement of hip, pelvis, spine | 13 | $822 | $63 |
Drugs they prescribed that Part D paid
$96,048
Pharmacies billed $96,048 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
637 generic and 130 brand-name prescriptions · $96,048 in drug cost · 50 antibiotic prescriptions to 33 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 170 | $15,584 | $92 |
| Premarin | 31 | $14,408 | $465 |
| Veozah | 14 | $12,329 | $881 |
| Estring | 12 | $7,234 | $603 |
| Yuvafem | 37 | $5,087 | $137 |
See all 15 drugs
| Estradiol | 170 | $15,584 | $92 |
| Premarin | 31 | $14,408 | $465 |
| Veozah | 14 | $12,329 | $881 |
| Estring | 12 | $7,234 | $603 |
| Yuvafem | 37 | $5,087 | $137 |
| Estradiol (Twice Weekly) | 36 | $3,800 | $106 |
| Valacyclovir | 44 | $1,910 | $43 |
| Progesterone | 53 | $1,495 | $28 |
| Clobetasol Propionate | 16 | $916 | $57 |
| Alendronate | 35 | $348 | $10 |
| Nitrofurantoin Mono-Macro | 30 | $316 | $11 |
| Clotrimazole-Betamethasone | 13 | $189 | $15 |
| Fluconazole | 23 | $123 | $5 |
| Zolpidem | 13 | $86 | $7 |
| Citalopram Hbr | 12 | $74 | $6 |
Year by year
| 2024 | 767 | 247 | None | 17% | $96,048 |
| 2023 | 666 | 202 | None | 20% | $91,876 |
| 2022 | 592 | 204 | None | 17% | $66,611 |
| 2021 | 595 | 185 | None | 19% | $64,719 |
| 2020 | 527 | 163 | None | 21% | $62,384 |
| 2019 | 594 | 171 | None | 23% | $77,661 |
| 2018 | 383 | 117 | 0% (0) | 29% | $61,974 |
| 2017 | 464 | 142 | None | 24% | $61,469 |
| 2016 | 503 | 144 | 0% (0) | None | $66,681 |
| 2015 | 492 | 128 | None | 33% | $50,001 |
| 2014 | 501 | 133 | None | 35% | $48,562 |
| 2013 | 399 | 91 | None | 32% | $32,920 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Myrbetriq | 20 | $15,907 | $795 |
| Premarin | 30 | $15,098 | $503 |
| Estradiol | 127 | $12,994 | $102 |
| Estradiol (Twice Weekly) | 32 | $4,825 | $151 |
| Yuvafem | 18 | $3,771 | $209 |
| Progesterone | 57 | $2,808 | $49 |
| Synthroid | 13 | $1,896 | $146 |
| Valacyclovir | 33 | $1,687 | $51 |
| Clobetasol Propionate | 15 | $761 | $51 |
| Nitrofurantoin Mono-Macro | 17 | $360 | $21 |
| Clotrimazole-Betamethasone | 15 | $327 | $22 |
| Medroxyprogesterone Acetate | 15 | $234 | $16 |
| Alendronate | 18 | $162 | $9 |
| Sumatriptan | 11 | $112 | $10 |
2022: 12 drugs
| Premarin | 26 | $12,362 | $475 |
| Estradiol | 114 | $10,797 | $95 |
| Estradiol (Twice Weekly) | 33 | $4,834 | $146 |
| Progesterone | 48 | $2,788 | $58 |
| Yuvafem | 12 | $2,501 | $208 |
| Valacyclovir | 30 | $1,883 | $63 |
| Clobetasol Propionate | 26 | $1,106 | $43 |
| Clotrimazole-Betamethasone | 19 | $437 | $23 |
| Nitrofurantoin Mono-Macro | 19 | $373 | $20 |
| Venlafaxine | 11 | $283 | $26 |
| Fluconazole | 19 | $131 | $7 |
| Clonazepam | 14 | $80 | $6 |
2021: 11 drugs
| Premarin | 24 | $11,309 | $471 |
| Estradiol | 114 | $10,791 | $95 |
| Yuvafem | 18 | $3,940 | $219 |
| Estradiol (Twice Weekly) | 23 | $2,111 | $92 |
| Valacyclovir | 22 | $1,600 | $73 |
| Progesterone | 32 | $1,321 | $41 |
| Nitrofurantoin Mono-Macro | 23 | $711 | $31 |
| Clobetasol Propionate | 22 | $653 | $30 |
| Clotrimazole-Betamethasone | 17 | $464 | $27 |
| Levothyroxine | 11 | $271 | $25 |
| Fluconazole | 23 | $175 | $8 |
2020: 19 drugs
| Estradiol | 82 | $11,830 | $144 |
| Premarin | 17 | $7,648 | $450 |
| Estrace | 18 | $6,564 | $365 |
| Yuvafem | 20 | $4,584 | $229 |
| Estradiol (Twice Weekly) | 20 | $2,335 | $117 |
| Estradiol (Once Weekly) | 12 | $2,149 | $179 |
| Climara | 12 | $1,936 | $161 |
| Progesterone | 21 | $1,793 | $85 |
| Valacyclovir | 26 | $1,556 | $60 |
| Solifenacin | 11 | $1,213 | $110 |
| Cefuroxime | 11 | $704 | $64 |
| Clobetasol Propionate | 15 | $686 | $46 |
| Nitrofurantoin Mono-Macro | 27 | $569 | $21 |
| Clotrimazole-Betamethasone | 15 | $344 | $23 |
| Levothyroxine | 11 | $269 | $24 |
| Fluconazole | 15 | $153 | $10 |
| Medroxyprogesterone Acetate | 11 | $151 | $14 |
| Zolpidem | 24 | $119 | $5 |
| Clonazepam | 12 | $41 | $3 |
2019: 17 drugs
| Estradiol | 95 | $14,742 | $155 |
| Vesicare | 11 | $8,737 | $794 |
| Premarin | 20 | $7,338 | $367 |
| Estrace | 17 | $7,144 | $420 |
| Progesterone | 24 | $4,800 | $200 |
| Acyclovir | 16 | $1,602 | $100 |
| Yuvafem | 19 | $1,531 | $81 |
| Valacyclovir | 16 | $812 | $51 |
| Nitrofurantoin Mono-Macro | 22 | $591 | $27 |
| Clobetasol Propionate | 19 | $471 | $25 |
| Zolpidem | 48 | $461 | $10 |
| Clotrimazole-Betamethasone | 20 | $458 | $23 |
| Medroxyprogesterone Acetate | 15 | $290 | $19 |
| Levothyroxine | 11 | $216 | $20 |
| Fluconazole | 18 | $192 | $11 |
| Trazodone | 13 | $109 | $8 |
| Clonazepam | 14 | $64 | $5 |
2018: 13 drugs
| Vesicare | 13 | $8,746 | $673 |
| Estradiol | 60 | $8,411 | $140 |
| Estrace | 19 | $8,307 | $437 |
| Yuvafem | 24 | $7,254 | $302 |
| Prempro | 16 | $6,033 | $377 |
| Progesterone | 22 | $3,073 | $140 |
| Jinteli | 13 | $762 | $59 |
| Nitrofurantoin Mono-Macro | 14 | $632 | $45 |
| Pravastatin | 13 | $379 | $29 |
| Medroxyprogesterone Acetate | 11 | $169 | $15 |
| Fluconazole | 11 | $137 | $12 |
| Zolpidem | 11 | $125 | $11 |
| Alendronate | 11 | $87 | $8 |
2017: 15 drugs
| Estrace | 30 | $9,124 | $304 |
| Yuvafem | 25 | $7,884 | $315 |
| Premarin | 19 | $6,168 | $325 |
| Estradiol | 59 | $6,030 | $102 |
| Prempro | 12 | $4,625 | $385 |
| Vagifem | 11 | $4,548 | $413 |
| Vesicare | 11 | $2,660 | $242 |
| Progesterone | 22 | $1,918 | $87 |
| Jinteli | 15 | $876 | $58 |
| Valacyclovir | 17 | $767 | $45 |
| Nitrofurantoin Mono-Macro | 16 | $407 | $25 |
| Medroxyprogesterone Acetate | 15 | $341 | $23 |
| Zolpidem | 18 | $265 | $15 |
| Spironolactone | 15 | $185 | $12 |
| Fluconazole | 15 | $171 | $11 |
2016: 12 drugs
| Vagifem | 40 | $13,821 | $346 |
| Premarin | 26 | $7,756 | $298 |
| Estrace | 25 | $7,259 | $290 |
| Prempro | 20 | $5,517 | $276 |
| Estradiol | 56 | $2,402 | $43 |
| Clobetasol Propionate | 14 | $1,591 | $114 |
| Oxybutynin Chloride Er | 13 | $1,076 | $83 |
| Nitrofurantoin Mono-Macro | 19 | $991 | $52 |
| Progesterone | 24 | $909 | $38 |
| Valacyclovir | 13 | $581 | $45 |
| Medroxyprogesterone Acetate | 26 | $536 | $21 |
| Levothyroxine | 14 | $126 | $9 |
2015: 14 drugs
| Vagifem | 22 | $7,116 | $323 |
| Premarin | 24 | $4,993 | $208 |
| Prempro | 19 | $4,819 | $254 |
| Estrace | 19 | $4,327 | $228 |
| Clobetasol Propionate | 14 | $3,159 | $226 |
| Estradiol | 57 | $2,769 | $49 |
| Progesterone | 20 | $1,340 | $67 |
| Acyclovir | 22 | $914 | $42 |
| Nitrofurantoin | 14 | $571 | $41 |
| Medroxyprogesterone Acetate | 33 | $532 | $16 |
| Clotrimazole-Betamethasone | 15 | $488 | $33 |
| Levothyroxine | 12 | $245 | $20 |
| Alendronate | 18 | $170 | $9 |
| Fluconazole | 15 | $88 | $6 |
2014: 16 drugs
| Premarin | 37 | $8,187 | $221 |
| Vagifem | 33 | $6,156 | $187 |
| Vesicare | 11 | $5,707 | $519 |
| Estrace | 23 | $3,772 | $164 |
| Vivelle-Dot | 18 | $2,863 | $159 |
| Estradiol | 44 | $2,060 | $47 |
| Acyclovir | 19 | $1,316 | $69 |
| Jinteli | 11 | $1,004 | $91 |
| Nitrofurantoin Mono-Macro | 16 | $667 | $42 |
| Clotrimazole-Betamethasone | 18 | $652 | $36 |
| Viorele | 13 | $584 | $45 |
| Medroxyprogesterone Acetate | 19 | $414 | $22 |
| Levothyroxine | 21 | $390 | $19 |
| Alendronate | 24 | $329 | $14 |
| Fluconazole | 26 | $184 | $7 |
| Oxybutynin Chloride | 11 | $177 | $16 |
2013: 13 drugs
| Premarin | 22 | $3,758 | $171 |
| Vagifem | 16 | $2,756 | $172 |
| Estrace | 16 | $2,565 | $160 |
| Vivelle-Dot | 16 | $2,472 | $154 |
| Nitrofurantoin Mono-Macro | 20 | $1,655 | $83 |
| Progesterone | 16 | $1,533 | $96 |
| Jinteli | 15 | $1,222 | $81 |
| Clotrimazole-Betamethasone | 14 | $573 | $41 |
| Estradiol | 38 | $488 | $13 |
| Alendronate | 33 | $441 | $13 |
| Medroxyprogesterone Acetate | 13 | $272 | $21 |
| Levothyroxine | 21 | $248 | $12 |
| Cefuroxime | 11 | $189 | $17 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 2 | 3 | None | $74 |
| 2021 | 1 | 1 | None | $22 |
| 2020 | 2 | 4 | None | $81 |
| 2019 | 4 | 9 | None | $156 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Aptima | $29 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2025-05-20 | Aptima | $29 |
See earlier years (2024, 2021, 2020, 2019)
2024: $74
| Hologic Sales and Service | Acessa Provu System | $61 | 2 payments
|
| Millicent US | None | $13 | 1 payment
|
2021: $22
| AbbVie | Lo Loestrin Fe | $22 | 1 payment
|
2020: $81
| AbbVie | Liletta | $64 | 3 payments
|
| Avion Pharmaceuticals | Balcoltra | $17 | 1 payment
|
2019: $156
| AbbVie | Orilissa | $84 | 4 payments
|
| Allergan | Lo Loestrin Fe | $42 | 3 payments
|
| Exeltis USA | Slynd | $19 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $11 | 1 payment
|
Professional record
- NPI
- 1194780957
- Licence
- CA G61752California G61752: Current · expires 2027-07-31
- Trained
- Howard University College of Medicine, 1986
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 15151 National Ave, Los Gatos, CA, 95032
- NPI first listed
- 2006-04-17
- NPI last updated
- 2010-07-01
This is when the NPI record was last certified, not a medical board exam.